Peterbio
Developer of gene and cell therapy technologies focused on cleavage-free, template-driven gene editing and sequence-specific gene repression. Emphasis on methods designed to minimize DNA breaks and immunogenic components to enable in vivo and ex vivo therapeutic applications, repeat dosing, and collaborations with industry and academia to advance treatments for monogenic and other genetic-component diseases.
Industries
Nr. of Employees
small (1-50)
Peterbio
Boston, Massachusetts, United States, North America
Products
RITDM™ 2.0 technology
A gene editing technology by PeterBio that repairs disease-causing genes and converts risk genes into protective genes, focusing initially on severe monogenic diseases and potentially applicable to chronic diseases with a genetic component.
T-LOCK™ gene repression technology
Gene repression technology that works by directly interacting with and binding to the gene to be repressed or silenced, preventing its transcription.
RITDM™ 2.0 technology
A gene editing technology by PeterBio that repairs disease-causing genes and converts risk genes into protective genes, focusing initially on severe monogenic diseases and potentially applicable to chronic diseases with a genetic component.
T-LOCK™ gene repression technology
Gene repression technology that works by directly interacting with and binding to the gene to be repressed or silenced, preventing its transcription.
Services
Collaborative discovery projects, technology licensing, scientific and technology development, and co-development opportunities with academic and industry partners.
Collaborative discovery projects, technology licensing, scientific and technology development, and co-development opportunities with academic and industry partners.
Expertise Areas
- Gene and cell therapy development
- Cleavage-free template-driven gene editing
- Sequence-specific DNA-binding protein engineering
- Ex vivo genome editing for therapeutic cell types
Key Technologies
- Cleavage-free template-driven gene editing
- Sequence-specific DNA-binding proteins (zinc-finger arrays)
- Helicase-mediated DNA strand opening (beta-wing motif)
- Single-stranded DNA modification templates
News & Updates
Presentation of the company's cleavage-free gene-editing technology and its mechanism combining sequence-specific DNA binding and helicase-based strand opening to enable templated editing without DNA breaks.
Peer-reviewed report describing a replication-interrupted template-driven editing approach that exposes single-stranded DNA for templated modification; demonstrates editing at endogenous human loci with low indel frequencies and undetectable off-target effects.
Announcement of Dirk Hondmann joining as CEO and expected role in advancing development and commercialization of the company's gene-editing and cell engineering technologies.
Presentation of the company's cleavage-free gene-editing technology and its mechanism combining sequence-specific DNA binding and helicase-based strand opening to enable templated editing without DNA breaks.
Peer-reviewed report describing a replication-interrupted template-driven editing approach that exposes single-stranded DNA for templated modification; demonstrates editing at endogenous human loci with low indel frequencies and undetectable off-target effects.
Announcement of Dirk Hondmann joining as CEO and expected role in advancing development and commercialization of the company's gene-editing and cell engineering technologies.